Silo Pharma, Inc. is a developmental stage biopharmaceutical company. The Company is focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as Post-traumatic stress disorder (PTSD), Alzheimer's disease, and other rare neurological disorders. It is engaged in acquiring and/or developing intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological disorders. It has entered into a sponsored research agreement with Columbia University, pursuant to which it has been granted an option to license certain patents and inventions relating to the treatment of Alzheimer’s disease and stress-induced affective disorders using Ketamine in combination with certain other compounds.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Annual Dividend Rate
Price/Cash Flow (TTM)